-
-
-
-
-
-
-
Braxia Scientific to Present at H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022
-
-
-
-
-
-
-
Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression
-
-
-
-
-
-
-
Braxia Scientific Reports Q3 2022 Financial Results; Company Leads in Psychedelic Research, Access and Therapist Training with First Multi-Dose Psilocybin Trial in Canada
-
-
-
-
-
-
-
Braxia Scientific Announces Voting Results from the Annual General Meeting of Shareholders
-
-
-
-
-
-
-
Braxia Scientific to Commence Landmark Clinical Trial to Conduct Canada's First Multiple-Dose Psilocybin Clinical Trial for Treatment Resistant Depression
-
-
-
-
-
-
-
Braxia Scientific to Discuss Psychiatric Treatment Discovery and Development with Oxford University Researchers at AIMday Experimental Medicine in Psychiatry on July 7, 2021
-
-
-
-
-
-
-
/R E P E A T -- Braxia Scientific Announces Symbol Change on OTC markets to "BRAXF"/
-
1,200,641 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

